Rainbow Child.

Why is Rainbow Childrens Medicare Ltd falling/rising?

As of 10-Jun, the stock price of Rainbow Childrens Medicare Ltd is rising to 1,340.05, reflecting a 1.02% increase. This rise is supported by strong fundamentals, increased investor participation, and a positive shift in market sentiment after a period of decline.

As of 10-Jun, the stock price of Rainbow Childrens Medicare Ltd is rising, currently at 1,340.05, reflecting an increase of 13.55 (1.02%). This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 0.51% today, indicating a positive performance relative to its peers. Additionally, there has been a trend reversal as the stock has gained after four consecutive days of decline, suggesting a potential shift in market sentiment.<BR><BR>Investor participation has also increased, with a delivery volume of 70.37 k on June 9, which is up by 4.27% compared to the five-day average. This rise in trading activity may signal growing confidence among investors. Furthermore, the stock's current price is higher than its 50-day, 100-day, and 200-day moving averages, although it remains lower than its 5-day and 20-day moving averages, indicating a mixed short-term trend but overall stability in the longer term.<BR><BR>The company's strong fundamentals support this positive movement, highlighted by a high return on capital employed (ROCE) of 19.70% and a low debt to EBITDA ratio of 1.64 times, showcasing its ability to manage debt effectively. Recent financial results have also been promising, with net sales reaching their highest at Rs 459.90 crore and a significant growth in profit after tax (PAT) of 21.8% compared to the previous four-quarter average. The earnings per share (EPS) have also peaked at Rs 7.59.<BR><BR>Moreover, the high institutional holdings at 38.37% suggest that knowledgeable investors are backing the company, which can further bolster confidence in its stock. Collectively, these factors contribute to the stock's rise as of the specified date.

What does Rainbow Child. do?

Rainbow Childrens Medicare Ltd is a small-cap company in the hospital industry, reporting net sales of 460 Cr and a net profit of 77 Cr for the quarter ending March 2026. It has a market cap of INR 13,468 Cr, a P/E ratio of 48.00, and a dividend yield of 0.23%.

Overview:<BR>Rainbow Childrens Medicare Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as Rainbow Children's Medicare Private Limited in 1998 and later converted to a public limited company, changing its name to Rainbow Children's Medicare Limited on November 20, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 460 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 77 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 13,468 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 48.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.23%<BR>- Debt-Equity: 0.27<BR>- Return on Equity: 16.97%<BR>- Price to Book: 8.13<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Which are the latest news on Rainbow Child.?

How big is Rainbow Child.?

As of 10th June, Rainbow Childrens Medicare Ltd has a market capitalization of 13,468.00 Cr, with recent net sales of 1,703.08 Cr and a net profit of 278.32 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Rainbow Childrens Medicare Ltd has a market capitalization of 13,468.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,703.08 Cr, while the sum of Net Profit for the same period is 278.32 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,468.19 Cr, and Total Assets amount to 2,347.40 Cr.

Should I buy, sell or hold Rainbow Childrens Medicare Ltd?

Are Rainbow Childrens Medicare Ltd latest results good or bad?

Rainbow Childrens Medicare Ltd's latest results show mixed performance, with a year-on-year profit growth of 5.59% but a quarter-on-quarter net profit decline of 3.61% and compressed operating margins, indicating operational challenges and raising concerns about sustainability. Overall, the results are more concerning than encouraging.

The latest results for Rainbow Childrens Medicare Ltd indicate a mixed performance, leaning towards the negative side. While the company achieved a year-on-year profit growth of 5.59%, it faced significant challenges in the most recent quarter. The net profit declined by 3.61% quarter-on-quarter to ₹72.53 crores, and revenue growth was minimal at just 0.15% sequentially. <BR><BR>Moreover, the operating margin has also compressed, falling to 33.0%, which is a decline from the previous quarter. This margin pressure, combined with the tepid revenue growth, raises concerns about the sustainability of the company's expansion in a competitive healthcare landscape. <BR><BR>Overall, while there are some positive year-on-year metrics, the sequential declines in both net profit and operating margin suggest that the company is grappling with operational challenges, making the latest results more concerning than encouraging.

When is the next results date for Rainbow Childrens Medicare Ltd?

The next results date for Rainbow Childrens Medicare Ltd is January 28, 2026.

The next results date for Rainbow Childrens Medicare Ltd is scheduled for January 28, 2026.

Is Rainbow Child. technically bullish or bearish?

As of December 1, 2025, the technical trend is mildly bearish, influenced by bearish indicators from the weekly MACD and moving averages, despite some bullish momentum in the weekly RSI and mixed monthly signals.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and Bollinger Bands indicating bearish conditions, while the daily moving averages also reflect a bearish outlook. The weekly RSI shows bullish momentum, but the overall monthly indicators remain mixed, with the KST showing bullish on a monthly basis. Dow Theory suggests a mildly bullish stance on the weekly timeframe, but with no clear trend on the monthly. The stock's recent performance against the Sensex has been negative across multiple time frames, further supporting the bearish sentiment.

How has been the historical performance of Rainbow Child.?

Rainbow Child has shown consistent growth over the past six years, with net sales increasing from 650.05 Cr in Mar'21 to 1,515.87 Cr in Mar'25, and profit after tax rising from 39.57 Cr to 244.23 Cr. The company has eliminated long-term debt and improved cash flow, indicating strong financial health.

Answer:<BR>The historical performance of Rainbow Child shows a consistent growth trend across various financial metrics over the past six years.<BR><BR>Breakdown:<BR>Rainbow Child's net sales have increased significantly from 650.05 Cr in Mar'21 to 1,515.87 Cr in Mar'25, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 719.39 Cr in Mar'20 to 1,515.87 Cr in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 173.10 Cr in Mar'21 to 540.90 Cr in Mar'25, although the operating profit margin slightly decreased from 33.07% in Mar'24 to 32.32% in Mar'25. Profit before tax rose from 55.70 Cr in Mar'21 to 330.00 Cr in Mar'25, while profit after tax increased from 39.57 Cr in Mar'21 to 244.23 Cr in Mar'25, showcasing improved profitability. The total assets of the company grew from 1,018.89 Cr in Mar'20 to 2,347.40 Cr in Mar'25, indicating a solid expansion in the asset base. Furthermore, the company has eliminated long-term borrowings, achieving a total debt of 0.00 Cr in Mar'25, which reflects a strong financial position. Cash flow from operating activities has also improved, rising from 142.00 Cr in Mar'21 to 395.00 Cr in Mar'25, contributing to a net cash inflow of 10.00 Cr in Mar'25. Overall, Rainbow Child has demonstrated robust growth and financial health over the years.

Who are the top shareholders of the Rainbow Child.?

The top shareholders of Rainbow Child include Ramesh Kancharla with 31.04%, 23 mutual funds holding 11.47%, and 188 foreign institutional investors with 23.69%. The highest public shareholder is the DSP Aggressive Hybrid Fund at 4.27%, while individual investors own 10.34% of the shares.

The top shareholders of Rainbow Child include the promoters, with Ramesh Kancharla holding the highest individual stake at 31.04%. Additionally, the company has significant institutional investment, with 23 mutual funds collectively holding 11.47% and 188 foreign institutional investors (FIIs) holding 23.69%. The highest public shareholder is the DSP Aggressive Hybrid Fund, which holds 4.27%. Individual investors also have a notable presence, owning 10.34% of the shares.

Who are the peers of the Rainbow Child.?

Peers of Rainbow Child include Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Dr. Agarwal's Health, Jupiter Life Line, Health.Global, and Kovai Medical. Rainbow Child has good management risk and a 1-year return of 29.99%, lower than Fortis Health's 62.86%.

Peers: The peers of Rainbow Child are Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Dr Agarwal's Hea, Jupiter Life Lin, Health.Global, and Kovai Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Narayana Hrudaya, Global Health, Dr Agarwal's Hea, Jupiter Life Lin, and Kovai Medical, while Average management risk is found at Fortis Health. Good management risk is noted for Rainbow Child and Health.Global. In terms of growth, Good growth is seen at Narayana Hrudaya, Dr Agarwal's Hea, and Health.Global, while Below Average growth is present at Aster DM Health., Rainbow Child, Krishna Institu., and Kovai Medical. For capital structure, Excellent capital structure is noted at Global Health and Krishna Institu., while Good capital structure is observed at Fortis Health, Rainbow Child, Dr Agarwal's Hea, and Kovai Medical, with Below Average capital structure at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 62.86%, while the lowest is Dr Agarwal's Hea with N/A, and Rainbow Child's 1-year return of 29.99% is lower than Fortis Health's. Additionally, Jupiter Life Lin has a negative six-month return of -3.18%.

Who are in the management team of Rainbow Child.?

As of March 2023, the management team of Rainbow Child includes Ramesh Kancharla (Chairman & Managing Director), Dinesh Kumar Chirla (Whole-time Director), and five Independent Directors: Aluri Rao Srinivasa, Anil Dhawan, Sundari Raviprasad Pisupati, Santanu Mukherjee, and Ashish Kapil (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Rainbow Child includes the following individuals:<BR><BR>1. Ramesh Kancharla - Chairman & Managing Director<BR>2. Dinesh Kumar Chirla - Whole-time Director<BR>3. Aluri Rao Srinivasa - Independent Director<BR>4. Anil Dhawan - Independent Director<BR>5. Sundari Raviprasad Pisupati - Independent Director<BR>6. Santanu Mukherjee - Independent Director<BR>7. Ashish Kapil - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Is Rainbow Child. overvalued or undervalued?

As of June 12, 2023, Rainbow Child is considered very expensive and overvalued with a PE ratio of 58.94, a Price to Book Value of 9.77, and an EV to EBITDA ratio of 29.64, despite a strong three-year stock performance of 199.47%.

As of 12 June 2023, the valuation grade for Rainbow Child. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 58.94, a Price to Book Value of 9.77, and an EV to EBITDA ratio of 29.64. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Rainbow Child. has a higher PE ratio than Max Healthcare Institute Ltd. at 100.29 and Apollo Hospitals Enterprise Ltd. at 69.03, both of which are also categorized as very expensive. The PEG ratio of 4.86 further underscores the overvaluation, especially when compared to peers like Narayana Hrudayalaya Ltd. with a PEG of 37.59. Despite a strong stock performance over the past three years, with a return of 199.47%, the current valuation metrics indicate that Rainbow Child. is not justified at its current price of 1408.40.

Has Rainbow Child. declared dividend?

Rainbow Childrens Medicare Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of June 27, 2025. The dividend yield is 0.21%, and total returns have varied across periods, showing significant growth over the long term despite short-term declines.

Rainbow Childrens Medicare Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.08%, the dividend return was 0.18%, resulting in a total return of -13.9%.<BR><BR>Over the past year, the price return was 8.36%, the dividend return was 0.46%, leading to a total return of 8.82%.<BR><BR>In the 2-year period, the price return was 52.26%, the dividend return was 0.94%, culminating in a total return of 53.2%.<BR><BR>For the 3-year period, the price return was 196.48%, the dividend return was 2.53%, resulting in a total return of 199.01%.<BR><BR>In the 4-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Similarly, in the 5-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Overall, Rainbow Childrens Medicare Ltd has declared a dividend and has shown varying total returns across different periods, with significant growth in the longer terms despite some negative performance in the short term. The dividend yield indicates a modest return relative to the share price.